First human test of novel heart failure drug begins
NCT ID NCT06625307
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new medicine called NNC0537-1482, designed to potentially treat heart failure. It is the first time this drug is given to humans, so healthy volunteers receive a single injection under the skin to check for safety and how the body processes it. Participants are randomly assigned to receive either the drug or a placebo. The results will help decide if further testing in heart failure patients is warranted.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- NNC0537-1482
- What this could lead to
- If safe and effective, this could lead to a new treatment option for people with heart failure.
- What could go wrong
- This is an early Phase 1 trial in healthy volunteers, so it may not work in heart failure patients or may have unexpected side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
ICON - location Groningen
Groningen, 9728 NZ, Netherlands
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Digital nurse companion: could an app ease the burden of chronic illness?
- Could continuing a common heart drug before surgery save lives?
- Could a new oral drug pass its first safety hurdle?
- Can a new drug play nice with common medicines? a trial investigates
- Poles apart? nordic walking may outpace standard rehab for heart failure
- Could a gentler tug on the Heart's reins spark recovery?